


Remarks

The amendments to the specification are being made to update the priority data and to add the requisite abstract of the disclosure. Applicants have replaced the medical use claims (claims 1-13) with method claims 21-34 to comply with MPEP 2173.05(q). Applicants have amended claim 14 to incorporate the features of claim 15. Applicants have also amended claims 16 to 20 to remove multiple dependencies. Accordingly, Applicants submit that no new matter has been added by these amendments.

Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **September 18, 2006**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue
Washington, D.C. 20004
202-739-3000

Respectfully submitted,
Morgan, Lewis & Bockius LLP



Robert Smyth
Registration No. 50,801